Stevanato Group (STVN) - EV/EBITDA Multiple
The predictability of cash flows for Stevanato Group S.p.A. is driven by strict government regulation of biopharmaceutical packaging. The historical EV/EBITDA trajectory visualizes this link to FDA certification inertia, where pharma behemoths purchase vials for years to avoid losing licenses. Currently, the metric stands at 11.35, confirming the resilience of a business that relies on the critical importance of syringes for the global vaccine market.
Analytical breakdowns for stevanatogroup.com (STVN)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Stevanato Group S.p.A.|STVN - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Stevanato Group|STVN - Aggregate Debt Obligations|Debt to Book Value Stevanato Group Corp|STVN - Company Long-Term Debts|Company Short-Term Debt Stevanato Group|Quick Ratio stevanatogroup.com
- business earnings and investment ratios data:
STVN - Company Net Income|Expected Profit Stevanato Group S.p.A.|STVN - Price to Earnings Multiple|Projected Price to Earnings Stevanato Group S.p.A.|STVN - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stevanato Group Corp|STVN - Operating income before deduction of amortization|Earnings per share for the last twelve months Stevanato Group|STVN - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months stevanatogroup.com|STVN - Net earnings per one share growth for the current year|Earnings growth forecast for next year Stevanato Group S.p.A.
Summary company analysis:Stevanato (STVN)
The specific positioning of Stevanato Group S.p.A. (STVN) as a monopolist in the production of biopharmaceutical packaging for GLP-1 drugs requires accounting for high production capital intensity. The historical EV/EBITDA trajectory reflects the ratio of total enterprise value to operating profit before interest and taxes, allowing investors to assess asset value relative to their ability to generate cash flow under current debt loads.
Competitors of Stevanato Group S.p.A.
Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Teleflex Corp (TFX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MMSI (Merit Medical Systems)|Enterprise Value to Operating Income Before Depreciation Ratio NVST|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ICU Medical ICUI|Business Value to Operating Income Before Depreciation XRAY|LMAT: Enterprise Value to EBITDA Ratio|ATRC - EV/EBITDA Multiple|STAAR Surgical Company (STAA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ChromaDex|ZIMV (ZimVie) - EV/EBITDA Multiple|Company Value to EBITDA AngioDynamics Inc ANGO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cerus Corp (CERS)|Teknova Inc - Enterprise Value to Operating Income Before Depreciation|Monogram Technologies - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio STSS (Sharps Technology Inc)|INFU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Utah Medical Products Inc. UTMD|korumedical.com (KRMD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NYXH - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MBOT|PDEX (pro-dex.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ZTEK|ELUT - Company Value to EBITDA|Milestone Scientific Corp - Enterprise Value to EBITDA Ratio|NEXGEL Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Retractable Tech - EV/EBITDA Multiple|HBIO - EV/EBITDA Multiple|Femasys (FEMY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation MHUA|POAI (Predictive Oncology Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple Callan JMB Corp|Enterprise Value to EBITDA Ratio ATRI (Atrion Corporation)|Enterprise Value to Operating Income Before Depreciation Ratio NURO
